These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 21885386)

  • 41. Supplemental oxygen improves exercise capacity in IPF patients with exertional desaturation.
    Arizono S; Furukawa T; Taniguchi H; Sakamoto K; Kimura T; Kataoka K; Ogawa T; Watanabe F; Kondoh Y
    Respirology; 2020 Nov; 25(11):1152-1159. PubMed ID: 32367694
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Unclassifiable-interstitial lung disease: Outcome prediction using CT and functional indices.
    Jacob J; Bartholmai BJ; Rajagopalan S; Egashira R; Brun AL; Kokosi M; Nair A; Walsh SLF; Karwoski R; Nicholson AG; Hansell DM; Wells AU
    Respir Med; 2017 Sep; 130():43-51. PubMed ID: 29206632
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Ambulatory and short-burst oxygen for interstitial lung disease.
    Sharp C; Adamali H; Millar AB
    Cochrane Database Syst Rev; 2016 Jul; 7(7):CD011716. PubMed ID: 27383922
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Independent Clinical Factors Relevant to Prognosis of Patients with Idiopathic Pulmonary Fibrosis.
    Song H; Sun D; Ban C; Liu Y; Zhu M; Ye Q; Yan W; Ren Y; Dai H
    Med Sci Monit; 2019 Jun; 25():4193-4201. PubMed ID: 31166938
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Mortality prediction in idiopathic pulmonary fibrosis: evaluation of computer-based CT analysis with conventional severity measures.
    Jacob J; Bartholmai BJ; Rajagopalan S; Kokosi M; Nair A; Karwoski R; Walsh SL; Wells AU; Hansell DM
    Eur Respir J; 2017 Jan; 49(1):. PubMed ID: 27811068
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Mortality on the Waiting List for Lung Transplantation in Patients with Idiopathic Pulmonary Fibrosis: A Single-Centre Experience.
    Bennett D; Fossi A; Bargagli E; Refini RM; Pieroni M; Luzzi L; Ghiribelli C; Paladini P; Voltolini L; Rottoli P
    Lung; 2015 Oct; 193(5):677-81. PubMed ID: 26216722
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Multi-dimensional Assessment of IPF Across a Wide Range of Disease Severity.
    Serajeddini H; Rogliani P; Mura M
    Lung; 2018 Dec; 196(6):707-713. PubMed ID: 30151723
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prediction of survival by texture-based automated quantitative assessment of regional disease patterns on CT in idiopathic pulmonary fibrosis.
    Lee SM; Seo JB; Oh SY; Kim TH; Song JW; Lee SM; Kim N
    Eur Radiol; 2018 Mar; 28(3):1293-1300. PubMed ID: 28929225
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Myositis-associated usual interstitial pneumonia has a better survival than idiopathic pulmonary fibrosis.
    Aggarwal R; McBurney C; Schneider F; Yousem SA; Gibson KF; Lindell K; Fuhrman CR; Oddis CV
    Rheumatology (Oxford); 2017 Mar; 56(3):384-389. PubMed ID: 28082622
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The predictors of mortality in IPF - Does emphysema change the prognosis?
    Tokgoz Akyıl F; Sevim T; Akman C; Aksoy E; Ağca M; Aktas O; Akyıl M
    Sarcoidosis Vasc Diffuse Lung Dis; 2016 Oct; 33(3):267-274. PubMed ID: 27758993
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Disease progression in idiopathic pulmonary fibrosis with mild physiological impairment: analysis from the Australian IPF registry.
    Jo HE; Glaspole I; Moodley Y; Chapman S; Ellis S; Goh N; Hopkins P; Keir G; Mahar A; Cooper W; Reynolds P; Haydn Walters E; Zappala C; Grainge C; Allan H; Macansh S; Corte TJ
    BMC Pulm Med; 2018 Jan; 18(1):19. PubMed ID: 29370786
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A simple dyspnoea scale as part of the assessment to predict outcome across chronic interstitial lung disease.
    Khadawardi H; Mura M
    Respirology; 2017 Apr; 22(3):501-507. PubMed ID: 27862639
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Investigation of parameters related to prognosis in diffuse parenchymal lung diseases prognosis in interstitial lung diseases].
    Canıvar C; Bingöl Z; Kılıçaslan Z; Çağatay T; Okumuş NG
    Tuberk Toraks; 2017 Sep; 65(3):210-219. PubMed ID: 29135399
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Nocturnal hypoxaemia is associated with adverse outcomes in interstitial lung disease.
    Troy LK; Young IH; Lau EMT; Wong KKH; Yee BJ; Torzillo PJ; Corte TJ
    Respirology; 2019 Oct; 24(10):996-1004. PubMed ID: 30933419
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Efficacy of thrombomodulin for acute exacerbation of idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia: a nonrandomized prospective study.
    Abe M; Tsushima K; Matsumura T; Ishiwata T; Ichimura Y; Ikari J; Terada J; Tada Y; Sakao S; Tanabe N; Tatsumi K
    Drug Des Devel Ther; 2015; 9():5755-62. PubMed ID: 26566367
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Associations between Patient-reported Outcomes and Death or Lung Transplant in Idiopathic Pulmonary Fibrosis. Data from the Idiopathic Pulmonary Fibrosis Prospective Outcomes Registry.
    Case AH; Hellkamp AS; Neely ML; Bender S; Dilling DF; Gulati M; Hotchkin DL; Huie TJ; Lancaster L; Snyder LD; Conoscenti CS; Palmer SM
    Ann Am Thorac Soc; 2020 Jun; 17(6):699-705. PubMed ID: 32040340
    [No Abstract]   [Full Text] [Related]  

  • 57. Prognostic significance of forced vital capacity decline prior to and following antifibrotic therapy in idiopathic pulmonary fibrosis.
    Aono Y; Nakamura Y; Kono M; Nakamura H; Yokomura K; Imokawa S; Toyoshima M; Yasui H; Hozumi H; Karayama M; Suzuki Y; Furuhashi K; Enomoto N; Fujisawa T; Inui N; Suda T
    Ther Adv Respir Dis; 2020; 14():1753466620953783. PubMed ID: 32928050
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Greater endurance capacity and improved dyspnoea with acute oxygen supplementation in idiopathic pulmonary fibrosis patients without resting hypoxaemia.
    Dowman LM; McDonald CF; Bozinovski S; Vlahos R; Gillies R; Pouniotis D; Hill CJ; Goh NSL; Holland AE
    Respirology; 2017 Jul; 22(5):957-964. PubMed ID: 28225205
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Physical activity in daily life in patients with idiopathic pulmonary fibrosis.
    Nishiyama O; Yamazaki R; Sano H; Iwanaga T; Higashimoto Y; Kume H; Tohda Y
    Respir Investig; 2018 Jan; 56(1):57-63. PubMed ID: 29325683
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Predictors of the clinical effects of pirfenidone on idiopathic pulmonary fibrosis.
    Arai T; Inoue Y; Sasaki Y; Tachibana K; Nakao K; Sugimoto C; Okuma T; Akira M; Kitaichi M; Hayashi S
    Respir Investig; 2014 Mar; 52(2):136-43. PubMed ID: 24636270
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.